The global pharmaceutical industry experienced a 23% drop in company filings mentions of cybersecurity in Q2 2023 compared with the previous quarter, with the highest share accounted for by Merck with 82% year-on-year increase, according to GlobalData’s analysis of over 438 pharmaceutical company filings. GlobalData’s Cybersecurity in Healthcare – Thematic Research market report helps get a detailed understanding on how Cybersecurity impacts the value chain in the pharmaceutical sector, and the leading Cybersecurity adopters and vendors in the market. Buy the report here.
Notably, cybersecurity was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of mobile health and robotics, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Merck had the greatest increase in references for cybersecurity in Q2 2023, compared with the previous quarter. GlobalData identified 20 cybersecurity-related sentences in the company's filings - 0.5% of all sentences - and an increase of 82% in Q2 2023 compared with Q2 2022. Regeneron Pharmaceuticals’s mentions of cybersecurity to 16 and WuXi AppTec’s by 200% to 15 and Recordati’s by 42% to 11.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for cybersecurity in Q2 2023 was 114.
To further understand GlobalData's analysis on Cybersecurity in Healthcare - Thematic Research market, buy the report here.